Back to News
Market Impact: 0.4
Jazz Pharmaceuticals Completes $820M Acquisition Of Actio Biosciences; Adds KCNT1 Epilepsy Therapy
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
Jazz Pharmaceuticals completed its acquisition of privately held Actio Biosciences for $820 million upfront. The deal expands Jazz's rare-disease-focused biopharmaceutical portfolio and is likely to be a meaningful company-specific strategic development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
JAZZ0.50
More News
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools
- Waymo’s backers valued it at $126 billion. The Alphabet division that houses it brought in $372 million last quarter—and lost $2.05 billion
- Nvidia weighs playing the cosigner for Nscale’s AI data center in West Virginia
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors